SUPRIYASupriya Lifescience Limited
Pharma · Biotechnology · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUPRIYA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 32.6% YoY
- • ROE: 17.5%
- • ROCE: 22.1%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • 6-month return: +19.3%
Bull case
- • Revenue growth: 32.6% YoY
- • ROE: 17.5%
- • ROCE: 22.1%
- • Price vs SMA200: above
Bear case
- • Profit growth: -30.8% YoY
- • Dividend yield: 0.10%
- • RSI: 40
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Profit growth: -30.8% YoY
- • Dividend yield: 0.10%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹35.66). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.